Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders for Matinas Biopharma Holdings, Inc. held on November 1, 2023. The meeting involved 127,057,908 shares, representing 58.48% of common shares outstanding as of the September 19, 2023 record date.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder votes. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent 10-K or 10-Q filings for financial performance details.
Material Changes and Shareholder Votes
Shareholders voted on four key proposals at the Annual Meeting:
- Proposal 1: Election of Directors. All seven nominees were elected to the Board of Directors. Vote counts ranged from approximately 56.9 million to 61.4 million "For" votes out of the total shares represented.
- Proposal 2: Executive Compensation. The advisory vote on named executive officer compensation was approved with 53,313,081 "For" votes against 11,991,145 "Against" votes.
- Proposal 3: Auditor Ratification. Shareholders approved the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 121,870,088 "For" votes.
- Proposal 4: Reverse Stock Split Authorization. Shareholders approved an amendment to the Certificate of Incorporation authorizing a reverse stock split at a ratio between 1-for-2 and 1-for-50. The Board retains sole discretion on the specific ratio, timing, and execution. Concurrently, the total authorized common shares will be reduced to 250,000,000.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The primary contingency noted is the discretionary nature of the reverse stock split; the Board has not yet determined if, when, or at what specific ratio the split will be implemented.
Key Facts for Investor Verification
- Verify the specific ratio and effective date of the reverse stock split, as the Board has not yet finalized these details.
- Confirm the impact of the reduced authorized share count (250,000,000) on future capital raising capabilities.
- Review the definitive proxy statement filed on September 19, 2023, for detailed biographies of the newly elected directors and executive compensation specifics.
- Check subsequent filings for the official announcement of the reverse stock split implementation.